Depomed (NASDAQ: DEPO) reported Q4 EPS of $0.48, $0.12 better than the analyst estimate of $0.36. Revenue for the quarter came in at $123.9 million versus the consensus estimate of $123.28 million.

For earnings history and earnings-related data on Depomed (DEPO) click here.